1 When Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box? Teri A. Longacre, MD Stanford Medicine Stanford California
2 pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
3 Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner have, or have had, within the past 12 months, which relates to the content of this educational activity and creates a conflict of interest. Dr. Teri A. Longacre declares she has no conflict(s) of interest to disclose. pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
4 Use of p16 in Cervical Squamous Lesions Tumor-suppressor p16 is overexpressed in cervical carcinomas p16 expression is altered by the effect of HPV on the retinoblastoma protein IHC staining for p16 has become standard practice in the evaluation of cervical lesions Although considered a surrogate marker for HPV infection in the appropriate setting, p16 does not, in general, act as a surrogate marker for HPV infection pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
5 Stimulation of cell-cycle progression by high-risk HPV Clin. Sci. (2006) 110,
6 p16 Immunohistochemistry Positive stain Diffuse (>80%) strong nuclear or nuclear and cytoplasmic reactivity block positive involving at least 1/3 basal layer: Correlates with presence of HR-HPV and diagnosis of dysplasia Grading of dysplasia MUST be based on histology J Low Genit Tract Dis. 2012;16: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
7 pi6 in Gynecologic Pathology: Panacea or Pandora s Box? Block positive p16
8 HSIL HSIL LSIL LSIL
9 p16 Immunohistochemistry Negative stain Cytoplasmic only staining Focal or patchy staining Discontinuous staining of basal layer Staining of upper layers but not basal layer J Low Genit Tract Dis. 2012;16: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
10 Cytoplasmic only interpret as negative
11 Discontinuous basal p16 interpret as negative
12 p16 Recommendations USE: HSIL vs. benign mimic Confirm diagnosis of CIN2 Disagreement about diagnosis of HSIL Negative biopsy with prior high-risk cytology: HSIL, ASC-H, AGC-NOS, ASC-US/HPV16+ pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
13 p16 Recommendations DO NOT USE: LSIL vs. benign mimic Morphology unequivocally diagnostic of: LSIL (CIN1) HSIL (CIN3) Negative for dysplasia pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
14 Squamous Morules p16
15 Neuroendocrine Carcinoma p16
16 Cervical Neuroendocrine Carcinoma <5% of all cervical cancer Most in mid 50 s Clinically aggressive Most bulky & deeply invasive with necrosis 50% high stage (FIGO III/IV) pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
17 Cervical Neuroendocrine Carcinoma Most express one or more neuroendocrine markers Often associated with AIS, HSIL, and conventional invasive cervical adenocarcinoma Both small and large cell types are p16-positive and harbor high-risk HPV (esp HPV 18) TREATED like neuroendocrine carcinoma elsewhere NOT like cervical cancer pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
18 Endometrial Neuroendocrine Carcinoma Most express one or more neuroendocrine markers Often associated with conventional endometrioid carcinoma Predominantly large cell type followed by mixed, and small cell Often PAX-8 negative May exhibit MMR deficiency (MLH1/PMS2 most common) May be p16-positive (24%) Am J Surg Pathol 2016;40: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
19 Summary: p16 in Cervical Squamous Lesions Should be strong, diffuse block-positive staining Many other lesions can have focal strong staining patterns Caution on limited sampling Do not use on LSIL lesions significance unknown Be clear about the question you are asking and be clear that you are using the right bioassay for that question pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
20 Use of p16 in Cervical Glandular Lesions Since AIS is assoc w/ high-risk HPV, AIS demonstrates diffuse, strong expression of p16 Ki-67 is also elevated & can be used as complimentary marker This can be used in confirming diagnosis of AIS in biopsy or curettage samples, but requires experience pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
27 p16 Predicament Strong, diffuse p16 in up to 10% of uterine corpus cancers in small samples p16 can be misleading in small samples Minimal deviation adenocarcinoma & other cervical special variant carcinomas are p16-negative p16 may not be sufficiently discriminating to use alone some use Ki-67 (mib1) pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
28 False Positive p16 Benign Lobular endocervical hyperplasia Malignant HPV-negative adenocarcinoma (55% patchy/diffuse p16) Am J Surg Pathol 2011; 35:633-46; Histopathology 2010;57: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
29 Summary: p16 in Cervical Glandular Lesions Should be strong, diffuse staining Many other lesions can have focal strong staining patterns Caution on limited sampling Be clear about the question you are asking and be clear that you are using the right bioassay for that question Use only after you have developed some experience with this pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
30 Use of p16 in Vulvar Squamous Lesions Exceptions: Differentiated (simplex) VIN Verrucous carcinoma Basal cell carcinoma Paget s disease pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
31 Differentiated (Simplex) VIN 10% of vulvar intraepithelial neoplasia Post-menopausal women Associated with lichen sclerosus, not HPV-related Typically identified adjacent to well-differentiated keratinizing carcinoma No counterpart in the cervix pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
32 Differentiated (Simplex) VIN Clinical appearance: Rough area with gray-white discoloration, or Ill-defined raised white plaque pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
33 Differentiated (Simplex) VIN: Architecture Expansion of basal layer with elongated, narrow rete ridges Epithelial thickness: acanthotic to atrophic Prominent parakeratosis pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
34 pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
35 Differentiated (Simplex) VIN: Cytology Abnormal maturation Enlarged keratinocytes with abundant, markedly eosinophilic cytoplasm in mid-to-superficial layers Superficial cell enlargement with pallor Nuclear atypia of the basal cell layer Enlarged, pleomorphic nuclei or Relatively small, hyperchromatic irregular nuclei pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
38 Differentiated (Simplex) VIN: Dermal Changes Fibrosis Lymphocytic infiltrate, may be lichenoid pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
41 Are There Hybrid Types? Usual HPV-related VIN in patients with lichen sclerosus Usual HPV-related VIN and non-hpv-related (differentiated [simplex]) VIN in same patient Usual basaloid non-hpv related VIN J Clin Pathol. 2007;60; ; Am J Surg Pathol. 2009;33: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
42 Vulvar Verrucous Carcinoma Rare, special variant of SCC Slow-growing, minimal metastatic potential Typically low-risk HPV (6, 11) Histology: Exophytic, hyperkeratotic fronds Cytologically bland squamous epithelium Well-circumscribed pushing border with chronic inflammation pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
45 Anogenital Basal Cell Carcinoma No squamous intraepithelial component Stromal retraction but may not be present CK5/6-pos, p63-pos BerEp4-pos, BCL2-pos p16 may be focally strong positive limited (small) sampling problem pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
52 Anogenital Paget s Disease Squamous hyperplasia with hyperkeratosis and parakeratosis in 90% of anal extra-mammary Paget s Pseudoepitheliomatous hyperplasia Fibroepithelioma-like Papillomatous (mimics HPV) Paget cells may be unapparent Paget cells may strongly express p16 Am J Surg Pathol 2000;24: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
60 Anogenital Paget s disease Primary (may rarely invade) CK7+/CK20-/HER2neu+ Secondary to anorectal or bladder cancer CK7+/CK20+/GATA3+ CK7+/-/CK20+/-/CDX2+ pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
61 Anogenital Paget s & HSIL Rare, but may coexist Paget cells are HPV-negative HSIL is HPV-positive pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
62 Summary: Use of p16 in Vulvar Lesions LAST recommednations VIN lesions may change over time (dvin vs HPV-VIN) Consider panel to diagnose unusual vulvar lesions (CK7, p16, S100, BerEp4) pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
63 Use of p16 in Metastatic Lesions Exceptions: Transitional cell carcinoma Metastatic neuroendocrine carcinoma pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
64 p16 in Bladder Neoplasms Urothelial carcinoma with squamous differentiation (33%) Primary bladder squamous cell carcinoma (31%) Primary bladder adenocarcinoma (67%)* *Both p16 and p53 in 33% Mod Pathol 2012;25: ; PLoS One 2014; 9:e95724 pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
65 p16 in Bladder Neoplasms Use p16 in conjunction with HPV ISH in the evaluation of cervical cancer vs urinary tract cancer Not all metastatic lower genital tract squamous cancer express p16 in strong diffuse pattern pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
66 Summary: Use of p16 in Metastatic Lesions In general, cannot be relied on for determining primary site Requires careful clinicopathologic correlation Consider HPV testing (in situ hybridization) pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
67 Use of p16 in Endometrial Glandular Lesions p16 (% cells) p53 (% cells) HPV Endocervical adenocarcinoma Diffuse, mod-strong (90-100%)??? Serous adenocarcinoma Diffuse, mod-strong (90-100%) Strong, diffuse (>90%) or null 45/49 Endometrioid adenocarcinoma Variable, weak-strong (10-90%)??? Am J Surg Pathol 2009;33: ; Int J Gynecol Pathol 2007;26: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
71 Papillary Syncytial Change (Metaplasia) Papillary syncytial change associated with stromal breakdown, atrophy, karyorrhectic debris Papillary syncytial metaplasia occurs over surface of endometrium, may be extensive, often mixed epithelial types May overlie atrophy, hyperplasia or carcinoma pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
72 Papillary Syncytial Change (Metaplasia) Decreased expression of ER Increased expression of p53 (although still wild-type staining) and p16, the latter marker typically being diffusely positive Low MIB1 proliferation index In problematic cases, IHC may result in a misdiagnosis Int J Gynecol Pathol 2012;31: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
73 Papillary Syncytial Change (Metaplasia) p53
74 Use of p16 in Uterine Mesenchymal Lesions p16 is overexpressed in uterine leiomyosarcomas by gene expression studies, but p16, p53, Ki-67, and other cell cycle regulatory markers are often not helpful in the distinction between leiomyomas with unusual features (mostly leiomyomas with bizarre nuclei) and leiomyosarcoma, as overlap in their expression is common. Am J Surg Pathol 2013;37: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
75 Leiomyoma with Bizarre Nuclei vs LMS LBN LMS Mitotic index (MF/10HPF) 10 >10 Tumor cell necrosis Absent Present Ki-67 (MIB-1) Low High p16 Low High p53 Negative Positive Am J Surg Pathol 2013;37: pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
76 Leiomyoma with Bizarre Nuclei p16
77 Summary p16 has transformed the diagnosis and treatment of lower genital tract squamous & glandular lesions p16 is only a surrogate and so there are many caveats & limitations to its utility HPV in situ or PCR may be required to establish definitive diagnosis in difficult cases Panels should always be utilized in the appropriate clinical context pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
78 Important Information Regarding CME/SAMs The Online CME/Evaluations/SAMs claim process will only be available on the USCAP website until September 30, No claims can be processed after that date! After September 30, 2017 you will NOT be able to obtain any CME or SAMs credits for attending this meeting. pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
79 pi6 in Gynecologic Pathology: Panacea or Pandora s Box?
Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive
2013 California Society of Pathologists 66 th Annual Meeting San Francisco, CA Atypical Glandular Cells to Early Invasive Adenocarcinoma: Cervical Cytology and Histology Christina S. Kong, MD Associate
VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node
The Clinical Significance of Stratifying Vulval Squamous Carcinoma into HPV and Non-HPV Related Variants C. BLAKE GILKS MD FRCPC Dept of Pathology, University of British Columbia Vulvar squamous cell carcinoma
Histopathology: Cervical HPV and neoplasia These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you need to learn about
chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence
HPV and Lower Genital Tract Disease Simon Herrington University of Edinburgh, UK Royal Infirmary of Edinburgh, UK Conflict of interest/funding X None Company: Product royalties Paid consultant Research
Hyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000 Thomas A. Bonfiglio, M.D. Professor Emeritus, Pathology and Laboratory Medicine University of Rochester Disclosures In the past 12 months,
Nephrogenic Adenoma Synonyms Nephrogenic metaplasia Mesonephric adenoma Definition Benign epithelial lesion of urinary tract with tubular, glandular, papillary growth pattern Most frequently in the urinary
Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose any relevant financial relationship
EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize
Demystifying Endometrial Hyperplasia A review from Diagnostic Histopathology 19:7 Dr R Hadden ST5 Histopathology Derriford Hospital Plymouth Endometrium Target for sex-steroid hormones Glands Stroma Proliferate
Gynecologic Cytology Fadi W. Abdul Karim, MD MEd Department of Anatomic Pathology Vice Chair Education RT PLMI Professor of Pathology Cleveland Clinic. Cleveland Ohio Disclosure of Relevant Financial Relationships
New Developments in Immunohistochemistry for Gynecologic Pathology Michael T. Deavers, M.D. Professor, Departments of Pathology and Gynecologic Oncology Immunohistochemistry in Gynecologic Pathology Majority
SQUAMOUS CELLS: Atypical squamous cells (ASC) - of undetermined significance (ASC-US) - cannot exclude HSIL (ASC-H) ASC refers to cytologic changes suggestive of SIL, which are qualitativley or quantitatively
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona firstname.lastname@example.org http://www.zheng.gynpath.medicine.arizona.edu/index.html
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
CINtec PLUS Cytology Interpretation training Objectives After reviewing this learning module, you will have a basic understanding of how to interpret CINtec PLUS Cytology, including: The mechanism of action
ISPUB.COM The Internet Journal of Pathology Volume 12 Number 1 A Papanicolau, G Lin Citation A Papanicolau, G Lin.. The Internet Journal of Pathology. 2010 Volume 12 Number 1. Abstract Intravascular endometrium
Salivary Glands 3/7/2017 Goals and objectives Focus on the entities unique to H&N Common board type facts Information for your future practice Salivary Glands Salivary Glands Major gland. Paratid. Submandibular.
& 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance Charles C Guo 1 and
Diagnostically Challenging Cases in Gynecologic Pathology Eric C. Huang, M.D., Ph.D. Department of Pathology and Laboratory Medicine University of California, Davis Medical Center Case 1 Presentation 38
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
Diseases of the breast (1 of 2) Introduction A histology introduction Normal ducts and lobules of the breast are lined by two layers of cells a layer of luminal cells overlying a second layer of myoepithelial
Question 1. Each of the following statements about cervical adenocarcinoma is true except: Adenocarcinoma of the Cervix SAMS a) A majority of women with cervical adenocarcinoma have stage I tumors at diagnosis.
Mixed Tumors of the Uterine Corpus and Cervix Marisa R. Nucci, M.D. Division of Women s and Perinatal Pathology Department of Pathology Brigham and Women s Hospital Boston, MA UCSF Current Issues in Anatomic
Glandular lesions in cervical cytology Margareta Strojan Fležar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia 2nd PANNONIA CONGRESS OF PATHOLOGY, SIÓFOK, HUNGARY, 17-19 MAY
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA 1 A good H & E helps! ADENOCARCINOMA DIAGNOSTIC CRITERIA Relatively uniform proliferation
DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS Jason L. Hornick, M.D., Ph.D. Director of Surgical Pathology and Immunohistochemistry Brigham and Women s Hospital Professor
Disclosure of Relevant Financial Relationships Monalisa Sur MBBS, FCPath(S.A), MMED(WITS), FRCPath(U.K), FRCP( C) Professor, Department of Pathology and Molecular Medicine Division of Anatomical Pathology
ThinPrep Pap Test History: 34 Year Old Female LMP: Day 20 Specimen Type: Cervical/Vaginal Case provided by Mark Tulecke, M.D. and Gabrielle Trawinski CT (ASCP), Mount Auburn Hospital, Cambridge, Massachusetts.
p16 Cervical HISTOLOGY Histology Compendium & Staining Atlas Chapter 1: An Introduction to p16...... 3 Normal Cervical Epithelium and the Cell Cycle....4 HPV Infection and Cervical Disease......................................
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE Ph.D. THESIS ENDOMETRIAL HYPERPLASIAS IN PERIMENOPAUSE SUMMARY SCIENTIFIC COORDINATOR: PROF. DR. MIHAI B. BRĂILA, Ph.D. Ph.D. Graduand:
Gynecologic Malignancies Kristen D Starbuck 4/20/18 Outline Female Cancer Statistics Uterine Cancer Adnexal Cancer Cervical Cancer Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial
Update in Salivary Gland Pathology Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016 Objectives Review the different appearances of a selection of salivary gland tumor types Establish
Pathology of the Prostate PathoBasic 24.01.17 Tatjana Vlajnic Overview Adenocarcinoma of the prostate Grading Special variants Mimickers of prostate adenocarcinoma Atrophy Inflammatory conditions Granulomatous
Follicular Lymphoma: the WHO and the WHERE? Yuri Fedoriw, MD Associate Professor of Pathology and Laboratory Medicine Director of Hematopathology University of North Carolina Chapel Hill, NC Disclosure
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
Variability of Pathologists Utilization of p16 and Ki-67 Immunostaining in the Diagnosis of Cervical Biopsies in Routine Pathology Practice and Its Impact on the Frequencies of Cervical Intraepithelial
Taking a PAP SMEAR Cervical Cancer : Pap smear George N Papanicolaou introduced cervical cytology in clinical practice in 1940 In 1945, PAP smear was endorsed by American cancer society as an effective
Case 1 Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno SAMO Interdisciplinary Workshop on Gynecological Tumors Lucern, October
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director of Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital SALIVARY GLAND FNA: PART II Oncocytic,
Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the
Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review Sandra Lee MD, FRCPC 1 *, Vikrant V. Sahasrabuddhe, MBBS, DrPH 2 *, Diana
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
Cervical Adenocarcinoma of Human Papillomavirus Positive and Human Papillomavirus Negative Tumors Edyta C. Pirog, MD, PhD Context. Cervical adenocarcinomas span a diverse group of tumors with several distinct
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR Last Revision Date July 2015 1 Site Group: Gynecologic Cancer Vulvar Author: Dr. Stephane Laframboise 1. INTRODUCTION
PAPILLARY PROLIFERATION OF THE ENDOMETRIUM: A BENIGN LESION SIMULATING ADENOCARCINOMA. Teresa Pusiol, Maria Grazia Zorzi, Doriana Morichetti U.O. Anatomia Patologica Ospedale S. Maria del Carmine Rovereto
Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics I have no financial interests
Done by khozama jehad Neoplasia of the cervix An overview of cervical neoplasia very import. Most tumors of the cervix are of epithelial origin and are caused by oncogenic strains of human papillomavirus
Malaysian J Pathol 2003; 25(2) : CERVICAL 139 143 VILLOGLANDULAR ADENOCARCINOMA CYTOLOGY CASE REPORT Villoglandular adenocarcinoma of cervix a tumour with bland cytological features: report of a case missed
What I Learned from 3 Cases and 3 Antibodies Melinda Sanders, M.D Vanderbilt University Medical Center Professor of Pathology Consultant in Breast Pathology Disclosure of Relevant Financial Relationships
THE AMEBICAN JOURNAL OF CLINICAL PATHOLOGY Copyright 1964 by The Williams & Wilkins Co. Vol. 42, No. 0 Printed in U.S.A. CARCINOMA IN SITU OF THE ENDOMETRIUM ISABELLE A. BUEHL, M.D., PRANK VELLIOS, M.D.,
Pseudomalignant Lesions of the Prostate Thomas M. Ulbright, M.D, Indiana University School of Medicine 1 Prostatic Atrophy Most common benign lesion of prostate misinterpreted as carcinoma Affects both
MBBS 2 nd Yr. Lecture Dr. Annie Cheung September 30, 2002 9:30 am LT2,G/F, Academic and Administration Block Faculty of Medicine Building UROGENITAL SYSTEM PATHOLOGY OF THE FEMALE GENITAL TRACT Learning
1 ACGME Competency / Milestone Assessment The Pap Test Ricardo R. Lastra, MD Zubair W. Baloch, MD, PhD Department of Pathology & Laboratory Medicine University of Pennsylvania, Perelman School of Medicine
Case 18 M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is: A. Pilomatrical carcinoma B. Adnexal carcinoma NOS C. Metastatic squamous cell carcinoma D.Primary squamous cell carcinoma
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 48, 409-416 (1975) Histopathology of Melanoma G. J. WALKER SMITH Department ofpathology, Yale University School ofmedicine, 333 Cedar Street, New Haven, Connecticut
Disclosures Parathyroid Pathology I have nothing to disclose Annemieke van Zante MD/PhD Assistant Professor of Clinical Pathology Associate Chief of Cytopathology Objectives 1. Review the pathologic features
AJMS Al Ameen J Med Sci (2 012 )5 (2 ):1 3 2-1 3 6 (A US National Library of Medicine enlisted journal) I S S N 0 9 7 4-1 1 4 3 C O D E N : A A J M B G ORIGI NAL ARTICLE Spectrum of Lesions in Cystoscopic
Sex Cord Stromal Tumors of the Testis Sex Cord Stromal Tumors of the Testis Charles Zaloudek, M.D. Professor, Department of Pathology University of California, San Francisco 505 Parnassus Ave., M563 San
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
THE DIFFICULT DIAGNOSIS IN THE URINARY BLADDER: A SELECTIVE CONSIDERATION, MULLERIAN AND MULLERIAN- LIKE CONDITIONS Robert H. Young, M.D. Benign and malignant müllerian lesions Mullerian-like appearances
Histol Histopathol (1 999) 14: 269-277 http://www.ehu.es/histol-histopathol Histology and Histo pathology Invited Re vie W Molecular genetics of ovarian carcinomas J. Diebold Pathological Institute, Ludwig-Maximilians-University
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
THE 1999 LONG COURSE ON PATHOLOGY OF THE UTERINE CORPUS AND CERVIX Problems in the Differential Diagnosis of Endometrial Hyperplasia and Carcinoma Steven G. Silverberg, M.D. Department of Pathology, University